Navigation Links
Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
Date:2/11/2013

EMERYVILLE, Calif., Feb. 11, 2013 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. 

Chest pain is the second leading cause of admittance to Emergency Departments in the US.  An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention.  The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.   Using a whole blood sample, the Omega-3 handheld system is designed to produce results in approximately 10 minutes at the site of first patient interaction, potentially reducing diagnosis of an MI by as much as an hour.  The cardiac test panel is the first developed for the Nanomix platform and extensions into other emergency medicine and infectious disease areas are planned to follow. 

About Nanomix Inc.

Nanomix's leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting.  Omega-3, the Nanomix mobile diagnostic platform, is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.  The compact size of the electronic and credit card sized disposable test cartridge can be configured to run a wide variety of tests from range of patient samples.

For more information, visit: http://www.nano.com

Contact:

David Ludvigson
dludvigson@nano.com
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA  94608
Phone:  1-510-428-5332


'/>"/>
SOURCE Nanomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
2. uniQure Initiates Phase I in Acute Intermittent Porphyria
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Sun City is the place to be on March 3rd to learn about the latest ... hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will be presented ... addition, prizes will be given away and light refreshments will be served. , As ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased ... has delved into this niche allowing those giving up their beloved pasta a chance ... grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
Breaking Medicine News(10 mins):